Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540829 | 0.82 | CES2 (0.53) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL5533299 | 0.82 | CES2 (0.53) | CES2MEN1FAAHMAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL2556211 | 0.81 | CES2 (0.52) | CES2MEN1FAAHMAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL28877 | 0.81 | CES2 (0.52) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL21318254 | 0.79 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL20838327 | 0.79 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL28292434 | 0.79 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL21448711 | 0.79 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL16431121 | 0.79 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL18597115 | 0.79 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | claimed |
| EP-4175967-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022006368-A2 | TRINUCLEOTIDE CAP ANALOGS, PREPARATION AND USES THEREOF | Life Technologies Corporation (US) | 2022-01-06 | — | — | WO | claimed |
| US-10968240-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2021-04-06 | — | — | US | claimed |
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2018-12-18 | — | — | US | claimed |
| US-20170029448-A1 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVEDDELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2017-02-02 | — | — | US | claimed |
| EP-2912045-A2 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | Molecular Transfer, Inc. (US) | 2015-09-02 | — | — | EP | claimed |
| WO-2014070687-A2 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2014-05-08 | — | — | WO | claimed |
| EP-2015780-B1 | NOVEL REAGENTS FOR TRANSFECTION OF EUKARYOTIC CELLS | MOLECULAR TRANSFER INC (US) | 2012-12-12 | — | — | EP | claimed |
| WO-2012142622-A1 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. (US) | 2012-10-18 | — | — | WO | claimed |
| US-7915230-B2 | Reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | MOLECULAR TRANSFER (US) | 2009-01-22 | — | — | US | claimed |
| EP-1198256-A4 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | LIPOSOME CORP (US) | 2004-06-16 | — | — | EP | claimed |
| EP-1198256-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME CORPORATION (US) | 2002-04-24 | — | — | EP | claimed |
| WO-2001000247-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 2001-01-04 | — | — | WO | claimed |
| EP-0964690-A4 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | LIPOSOME CO INC (US) | 2000-03-29 | — | — | EP | claimed |
| EP-0964690-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998016240-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 1998-04-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968240-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | CES2 2832/4885MEN1 604/4885FAAH 3332/4885 |
| US-10155780-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | CES2 2867/4885MEN1 784/4885FAAH 3166/4885 |
| US-20170029448-A1 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVEDDELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | PHOSPHO1, PLTP, MBOAT7 | CES2 3161/4885MEN1 700/4885FAAH 3226/4885 |
| US-20090023215-A1 | Novel reagents for transfection of eukaryotic cells | FUS, PHAX, PICALM | CES2 3710/4885MEN1 1559/4885FAAH 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.